The impact of innovative technologies in healthcare has been significant in recent years. Digital health solutions are becoming available throughout Europe and are becoming more and more popular among patients, providers and researchers. Wearables and sensors integrated into mobile phones and other portable devices allow the population to monitor their health and doctors to monitor in near real time. The acceptance of these solutions is increasing. The size of the wearable medical device market in the EU is estimated to grow from around € 2,241 million this year to € 5,290 million by 2026.
The size of the wearable medical device market in the EU is estimated to grow from around € 2,241 million this year to € 5,290 million by 2026.
While digital solutions have advanced patient care in the EU, digital innovation in pharmaceutical R & D is still in its infancy. Early on, it suggests that data and digital will revolutionize current practices in drug research, discovery and development, allowing new generations of drugs to be discovered faster.
At Sanofi, artificial intelligence (AI) has allowed us to generate leads for new molecules that are currently moving into our pharmaceutical portfolio. New data solutions, guided by scientists’ expertise, can also discover multi-target molecules that have the potential to improve the way complex diseases are treated.
At the same time, real-world data and real-world evidence make clinical trials more efficient by reducing the number of patients that need to be enrolled or by leveraging digital biomarkers to enable early validation or improvement of results. I am aiming for it.
These advances open up endless possibilities for discovering new therapies and achieving better results for patients. Payers have also been able to develop pricing and reimbursement models that include real-world evidence-based valuations to integrate digital healthcare solutions. This represents an important paradigm shift in healthcare.
Given the recently adopted regulations on health technology assessment (EU framework for assessing the value of medicines), new data standards need to be recognized and adopted. It is important to align the evidence received by the regulatory body with scientific and digital development.
In addition, as data sources inevitably evolve and expand, as an industry, we regularly and collaboratively identify their impact and value with partners, policy makers and regulators to implement the current EU framework. We need to ensure common interpretation and acceptance to leverage.
Real-world data and real-world evidence make our clinical trials more efficient … opening up endless possibilities for discovering new therapies and achieving better results for patients. ..
Governments need to invest to accelerate the adoption of new digital solutions while improving digital capabilities and infrastructure among medical professionals. Medical authorities have restricted the use of standardized data or AI to promote national and cross-border anonymization and standardized dataset sharing and interoperability, and to improve R & D productivity and medical management. Should be abolished. This is all important to ensure that we continue to promote better medicines and treatments for our patients.
At Sanofi, we are already playing our part. We recently announced a deep partnership with Owkin that focuses on federated learning for AI and medical research. Leveraging Owkin’s expertise in AI and data, we combine efforts to build robust disease models from a variety of research institutes and hospitals. This partnership will help optimize clinical trial design and detect predictive biomarkers of disease and treatment options in oncology. And this is just the beginning of our ambitions for AI-driven drug discovery.
We hope that the European Health Data Space will help build trust with individuals who expect to gain greater access and control to their health data after EHDS becomes operational. If successful, EHDS will leverage a large EU-wide data pool to create the trust framework needed for success, instead of managing many data islands across 27 EU member states individually. You can get the opportunity. This will accelerate understanding of the disease, R & D efforts, and the development of medicines that meet the needs of patients. However, the time when EHDS works is before the digital environment becomes overly complex.
At Sanofi, we are committed to implementing digital health and data solutions that are transforming the current drug development, clinical trials and manufacturing paradigms. Today, we are more driven than ever to realize that patients will benefit.
..
